Skip to main content
J

Jiangxi Synergy Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300636 LEI · 836800AMA4MDGZBPAQ18 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2026-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300636

About Jiangxi Synergy Pharmaceutical Co.,Ltd.

https://www.jxsynergy.com

Jiangxi Synergy Pharmaceutical Co.,Ltd. specializes in the research, development, production, and sale of steroid hormone active pharmaceutical ingredients (APIs) and their intermediates. The company maintains a comprehensive product portfolio that includes progesterone, medroxyprogesterone acetate, and various corticosteroid derivatives. Utilizing advanced chemical synthesis and fermentation technologies, the firm provides high-purity components for the global pharmaceutical market. Its operations are characterized by a commitment to rigorous quality management systems and compliance with international manufacturing standards. The company serves a diverse clientele of pharmaceutical formulators, focusing on delivering specialized chemical solutions for hormonal therapies and related medical applications.

Recent filings

Filing Released Lang Actions
2025年度募集资金存放、管理与使用情况专项报告的鉴证报告
Audit Report / Information Classification · 1% confidence The document is a CPA “鉴证报告” (attestation/audit report) issued by Lixin (BDO China) on the company’s special‐purpose report (募集资金存放、管理与使用情况专项报告). It is a standalone audit‐style assurance report under Chinese securities rules, not a full annual report, earnings release, or announcement. Therefore it matches the “Audit Report / Information” category.
2026-04-28 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 1% confidence The document is a standalone summary table of non-operating funds occupation and other related-party fund dealings for fiscal year 2025, approved by the board on 27 April 2026. It does not contain full financial statements (Annual Report/10-K), audit opinions, earnings highlights, or dividend notices. It reads as a regulatory disclosure schedule rather than a complete report or announcement of a meeting outcome. Therefore, it falls into the general “Regulatory Filings” category (RNS).
2026-04-28 Chinese
招商证券股份有限公司关于江西同和药业股份有限公司使用部分闲置自有资金进行现金管理的核查意见
Regulatory Filings Classification · 1% confidence The document is a sponsor’s verification opinion (“核查意见”) issued by China Merchants Securities regarding Jiangxi Tonghe Pharmaceutical’s plan to use idle funds for cash management, prepared under Shenzhen Stock Exchange listing rules. It is not an annual or interim financial report, not an earnings release, not a proxy or voting result, and not a capital raise or share transaction. It is a regulatory disclosure required by exchange rules and does not fit any more specific category, so it falls under the fallback category for general regulatory announcements (RNS).
2026-04-28 Chinese
独立董事2025年度述职报告（宛虹）
Governance Information Classification · 1% confidence The document is an “Independent Director 2025 Annual Work Report,” detailing the activities, meeting attendance, committee work, and governance duties of an independent board member. It is not a financial earnings release, capital update, proxy, or legal notice. It concerns the company’s governance practices and oversight by an independent director, fitting the Governance Information category.
2026-04-28 Chinese
2025年度内部控制自我评价报告
Audit Report / Information Classification · 1% confidence The document is titled “2025年度内部控制自我评价报告” (2025 Internal Control Self-Evaluation Report) and provides a standalone assessment of the company’s internal control design, operation, and effectiveness as of year-end. It is not a full annual or interim financial report, nor an earnings release or dividend notice. Instead it is a specific audit-related compliance report on internal control, matching the definition of a standalone audit/internal control report under “Audit Report / Information” (AR).
2026-04-28 Chinese
2025年度募集资金存放、管理与使用情况的专项报告
Capital/Financing Update Classification · 1% confidence The document is titled “2025年度募集资金存放、管理与使用情况的专项报告” (Special Report on the Deposit, Management and Use of Raised Funds for 2025). It provides a full breakdown of capital raised in a previous private placement, the amounts raised, costs, account balances, investment projects, and cash management activities. It is not an announcement of a new financing or a high-level earnings summary; rather it is a detailed regulatory‐required update on the use of previously raised funds. This matches the Capital/Financing Update category.
2026-04-28 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.